sunho biologics

Deals ramp up in Asia’s healthcare space with cancer focus

An acquisition in Hong Kong by the New Frontier Group, an IPO by Sunho Biologics on the HKEX and a $1.5bn investment into Singapore by AstraZeneca, are signs that investments in next generation cancer treatments are increasing in the region.
May 28, 2024